Comparative Analysis of Hepatocellular Carcinoma Patients with and Without Type 2 Diabetes Mellitus

Short Communication

Austin J Gastroenterol. 2023; 10(1): 1121.

Comparative Analysis of Hepatocellular Carcinoma Patients with and Without Type 2 Diabetes Mellitus

Annie Shergill, MD*

Clovis Community Hospital, Clovis, CA

*Corresponding author: Annie Shergill, MD Clovis Community Hospital, Clovis, CA. Email: shergill7590@yahoo.com

Received: July 26, 2023 Accepted: August 17, 2023 Published: August 24, 2023

Abstract

Purpose of the Study: To evaluate the clinical impact of Type 2 Diabetes Mellitus (T2DM) in patients with Hepatocellular Carcinoma (HCC) in comparison to those without T2DM.

Methods: Retrospective study, HCC data obtained from public domain (kaggle.com).

Summary of Results Obtained: Mean age in the diabetic and non-diabetic groups were 70.4 and 62.08 years respectively. There was a female preponderance seen in both groups. Mean aspartate aminotransferase and alanine aminotransferase (AST/ALT) values in diabetic group were 81.42/54.8 U/L and in non-diabetic group were 116.72/77.4 U/L (p=0.19). Mean International Normalized Ratio (INR) in diabetic and non-diabetic groups were 1.51 and 1.34 respectively (p=0.32). Mean total bilirubin values in diabetic and non-diabetic groups were 2.39 and 1.95 mg/dL respectively (p=0.63). Total number of patients with varices were 33 in the diabetic and 32 in the non-diabetic group (p=0.59). Total number of patients with portal hypertension were 33 in the diabetic and 34 in the non-diabetic group (p=0.32). Portal venous thrombosis was found in 9 patients in the diabetic and 12 patients in the non-diabetic group (p=0.67). Metastatic disease was seen in 10 patients in the diabetic and 12 patients in the non-diabetic group (p=0.74).